Patents by Inventor Laszlo Hackler
Laszlo Hackler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220064167Abstract: The present invention relates to novel imidazo[1,2-b]pyrazole carboxamide and carbothioamide derivatives of general formula (V), and the advantageous derivatives and pharmaceutically acceptable salts thereof, the synthesis thereof, and medicinal and/or pharmaceutical composition comprising these compounds thereof and synthesis thereof, and for use as a medicament, for use in the treatment of different diseases, advantageously of cancer. The subject compounds are advantageously for use in the treatment of solid malignancies, advantageously breast, lung, melanoma, gliomas, and myeloproliferative and myelodysplastic neoplasms, acute myelogenous/myeloid leukemias and colon cancer by the differentiation and subsequent apoptosis of pre-matured myeloid leukemic cells or myeloid-derived suppressor cells and/or by direct effect on solid tumors.Type: ApplicationFiled: May 17, 2019Publication date: March 3, 2022Applicant: AVIDIN KFT.Inventors: András DEMJÉN, László PUSKÁS, Ivan KANIZSAI, Gábor SZEBENI, Anikó ANGYAL, Márió GYURIS, László HACKLER
-
Patent number: 10919939Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic analogs of endomorphin. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.Type: GrantFiled: April 3, 2017Date of Patent: February 16, 2021Assignees: The Administrators of the Tulane Educational Fund, United States Department of Veterans AffairsInventors: James E. Zadina, Laszlo Hackler
-
Publication number: 20190330188Abstract: Enantiomer derivatives of 8-hydroxyquinoline derivatives with general formula (I) and (II) and the synthesis thereof and pharmaceutically acceptable salts and metal complexes thereof, and the medicinal and/or pharmaceutical compositions comprise these compounds: The compounds according to the invention can be used preferably as cytoprotective, neuroprotective, cardioprotective, anxiolytic and antidepressant agent for treatment of neuropsychiatric and neurologic diseases and diseases in connections with transplantations and with ischemia and reperfusion injuries thereof, and inhibition of organ, advantageously skin graft rejection.Type: ApplicationFiled: May 13, 2019Publication date: October 31, 2019Applicants: AVIDIN Co. Ltd, SONEAS Research Co. Ltd., Synaging SASInventors: László PUSKÁS, István KANIZSAI, Thierry PILLOT, Márió GYURIS, András SZABÓ, Ferenc TAKÁCS, László HACKLER
-
Patent number: 10287265Abstract: Our invention relates to novel enantiomer derivatives of 8-hydroxyquinoline derivatives with general formula (I) and (II) and the synthesis thereof and pharmaceutically acceptable salts and metal complexes thereof, and the medicinal and/or pharmaceutical compositions comprising these compounds. The essence of the subject matter of the invention relates to the fact that prior art discloses the biological effect and characteristics only of the racemic products, the novel enantiomer derivatives according to the invention appear in our application for the first. The subject matter of the invention furthermore relates to a novel, stereoselective synthesis for the preparation of the novel enantiomer derivatives according to the invention. The novel medicinal and/or pharmaceutical compositions comprising these enantiomers are suitable for the treatment of the named diseases, and the enanatiomers are used for manufacture of these compositions.Type: GrantFiled: March 9, 2016Date of Patent: May 14, 2019Assignees: AVIDIN Co. Ltd., SONEAS Research Co. Ltd., Synaging SASInventors: László Puskás, István Kanizsai, Thierry Pillot, Márió Gyuris, András Szabó, Ferenc Takács, László Hackler
-
Publication number: 20180222940Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.Type: ApplicationFiled: September 14, 2017Publication date: August 9, 2018Applicants: The Administrators of the Tulane Educational Fund, United States Department of Veterans AffairsInventors: James E. ZADINA, Laszlo HACKLER
-
Publication number: 20170369531Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2, and in some embodiments, a 2?,6?-dimethyltyrosine (Dmt) residue in place of the N-terminal tyrosine residue a position 1. These peptide analogs exhibit increased solubility compared to similar tetrapeptide analogs while maintaining favorable or improved therapeutic ratios of analgesia to side effects.Type: ApplicationFiled: March 6, 2017Publication date: December 28, 2017Applicants: The Administrators of the Tulane Educational Fund, Department of Veterans Affairs (US)Inventors: James E. ZADINA, Laszlo HACKLER
-
Publication number: 20170362276Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic analogs of endomorphin. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.Type: ApplicationFiled: April 3, 2017Publication date: December 21, 2017Applicants: The Administrators of the Tulane Educational Fund, United States Department of Veterans AffairsInventors: James E. ZADINA, Laszlo HACKLER
-
Publication number: 20170197936Abstract: Our invention relates to novel enantiomer derivatives of 8-hydroxyquinoline derivatives with general formula (I) and (II) and the synthesis thereof and pharmaceutically acceptable salts and metal complexes thereof, and the medicinal and/or pharmaceutical compositions comprising these compounds. The essence of the subject matter of the invention relates to the fact that prior art discloses the biological effect and characteristics only of the racemic products, the novel enantiomer derivatives according to the invention appear in our application for the first. The subject matter of the invention furthermore relates to a novel, stereoselective synthesis for the preparation of the novel enantiomer derivatives according to the invention. The novel medicinal and/or pharmaceutical compositions comprising these enantiomers are suitable for the treatment of the named diseases, and the enanatiomers are used for manufacture of these compositions.Type: ApplicationFiled: March 9, 2016Publication date: July 13, 2017Inventors: László PUSKÁS, István Kanizsai, Thierry Pillot, Márió Gyuris, András Szabó, Ferenc Takács, László Hackler
-
Patent number: 9382229Abstract: Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed.Type: GrantFiled: February 15, 2012Date of Patent: July 5, 2016Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Donald J. Zack, Cynthia Berlinicke, Laszlo Hackler, Zhiyong Yang, Joseph P. Steiner, Tomas Vojkovsky, Dana Ferraris, Barbara S. Slusher, James Inglese
-
Publication number: 20160176930Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated amino acid and (ii) a D-amino acid substitution in position 2. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.Type: ApplicationFiled: December 18, 2015Publication date: June 23, 2016Applicants: The Administrators of the Tulane Educational Fund, United States Department of Veterans AffairsInventors: James E. ZADINA, Laszlo HACKLER
-
Publication number: 20160009764Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2, and in some embodiments, a 2?,6?-dimethyltyrosine (Dmt) residue in place of the N-terminal tyrosine residue a position 1. These peptide analogs exhibit increased solubility compared to similar tetrapeptide analogs while maintaining favorable or improved therapeutic ratios of analgesia to side effects.Type: ApplicationFiled: September 4, 2015Publication date: January 14, 2016Applicants: DEPARTMENT OF VETERANS AFFAIRS (US), THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: James E. ZADINA, Laszlo HACKLER
-
Publication number: 20140187540Abstract: Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed.Type: ApplicationFiled: February 15, 2012Publication date: July 3, 2014Applicant: The Johns Hopkins UniversityInventors: Donald J. Zack, Cynthia Berlinicke, Laszlo Hackler, Zhiyong Yang, Joseph P. Steiner, Tomas Vojkovsky, Dana Ferraris, Barbara S. Slusher, James Inglese
-
Patent number: 8716436Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.Type: GrantFiled: May 22, 2012Date of Patent: May 6, 2014Assignees: The Administrators of the Tulane Educational Fund, U.S. Department of Veterans AffairsInventors: James E. Zadina, Laszlo Hackler
-
Publication number: 20120322740Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.Type: ApplicationFiled: May 22, 2012Publication date: December 20, 2012Applicants: UNITED STATES DEPARTMENT OF VETERANS AFFAIRS, THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: James E. ZADINA, Laszlo HACKLER
-
Patent number: 6303578Abstract: This invention relates to certain peptides and linear and cyclic analogs thereof that bind to the mu (morphine) opiate receptor with higher affinity, selectivity and potency than currently available peptides. This invention also relates to pharmaceutical preparations containing an effective amount of the peptides or salts thereof, and methods for providing analgesia, relief from gastrointestinal disorders such as diarrhea, and therapy for drug dependence containing a pharmaceutically effective amount of the peptides.Type: GrantFiled: February 18, 1999Date of Patent: October 16, 2001Assignee: Administrators of the Tulane Educational FundInventors: James E. Zadina, Abba J. Kastin, Laszlo Hackler
-
Patent number: 5885958Abstract: This invention relates to certain peptides and linear and cyclic analogs thereof that bind to the mu (morphine) opiate receptor with higher affinity, selectivity and potency than currently available peptides. This invention also relates to pharmaceutical preparations containing an effective amount of the peptides or salts thereof, and methods for providing analgesia, relief from gastrointestinal disorders such as diarrhea, and therapy for drug dependence containing a pharmaceutically effective amount of the peptides.Type: GrantFiled: March 25, 1997Date of Patent: March 23, 1999Assignee: Administrators of the Tulane Educational FundInventors: James E. Zadina, Abba J. Kastin, Laszlo Hackler